Sherook

One of the hardest conversations in #Multiplemyeloma, now with a NEW DATE. Pleased to share the revised date for our upcoming session with Dr Shaji Kumar sir, Mayo Clinic on: ULTRA-HIGH-RISK AND HIGH-RISK MYELOMA: Recognizing Dangerous Biology Early and Choosing Action Before the Disease Outruns Us In High-Risk myeloma, the challenge is not only identifying risk on paper but also knowing when biology should alter strategy. 📅 21 May 2026 ⏰ 6:00- 7:00 PM IST 🌍 7:30- 8:30 AM Rochester time ▪️Registration link - rx-events.live/InnovationsInH… If you have any questions to discuss, please DM me. 📩 #Highriskmyeloma #mmsm #multiplemyeloma @myelomaMD @IndMyAcGp @IMFmyeloma @Myeloma_mSMART @theMMRF @MM_Hub @RahulDoc2

Review series on clonal hematopoiesis: how should clinicians approach clonal hematopoiesis in practice? This review outlines current strategies for risk assessment, monitoring, and clinical decision-making. haematologica.org/article/view/1…

Review series on clonal hematopoiesis: can clonal hematopoiesis be targeted therapeutically? This review explores emerging strategies aimed at modifying clonal expansion and disease risk. haematologica.org/article/view/1…

@mehak_trehan So many BCMA targeted therapies now. Teclistamab, Elranatamab now, Blenrep and CARTs soon. We need to find an ideal sequencing of these immunotherapies available, which I think is a serious dilemma in the coming days. With Elrana now in market, the prices will also come down.

1/5 With Elranatamab JUST NOW launched in India, the BCMA bispecific discussion is no longer theoretical. The active question is: Elranatamab vs Teclistamab : which is better? Both target BCMA×CD3. Both are SC. Both are used in heavily pretreated RRMM. The real question is- Can we match the right bispecific to the right myeloma biology and the right healthcare system? #MultipleMyeloma #BCMA #BispecificAntibodies #mmsm @RahulDoc2 @IndMyAcGp @MirghSumeet @EshaKaul1 @nikhil91sjmc

Our attempt to summarize infection PPx for bsAbs across diseases & targets succinctly… Thanks @KRejeski @JoshuaHillMD @BloodPortfolio for this! Relevant to both lymphoma and myeloma. BCMA bsAbs are unique… use true IVIG PPx, don’t wait for Gr3+ infection or arbitrary IgG ⬇️!

Pleased to share our recent publication @BloodPortfolio @ASH_hematology @utswcancer @ldandersonjr @HadidiSamer @UAMSMyeloma #mmsm #bmtsm Actual patients cases with difficult to treat entity and nice smear figures with suggested treatment algorithms and a look into the future How I Treat Plasma Cell Leukemia ➡️ ashpublications.org/blood/article/…

Seeking your valuable Experiences and Add Ons. @VincentRK @myelomaMD @NikhilMunshiMD @RahulBanerjeeMD @MeeraMohanMD @UdayYanamandra @NSidharthan @SameerMelinkeri @DrPMPGI @nikhil91sjmc @IndMyAcGp @dixit_hemat @DrNikitaMehra

Lambda 2522 → <1.34 mg/L. In weeks. That’s talquetamab bridging in aggressive EMD. Got the patient to CAR-T. Ended MRD-negative. Speed is therapy. #MultipleMyeloma #Talquetamab #CART

Talquetamab bridging: Turning uncontrolled EMD into CAR-T before BCMA CART.

1/ In NDMM, is Daratumumab the new norm - or are we letting PFS excitement outrun LMIC reality? Because yes: if the endpoint is PFS, Dara is winning. But if the endpoint is value, the debate is very much alive. #mmsm

When frontline myeloma data evolve faster than access, sequencing becomes more than science : it becomes strategy! ✨ Join us for an Expert Roundtable on: Sequencing Daratumumab and Transplant in Newly Diagnosed Multiple Myeloma Across LMIC Settings Chaired by @VincentRK , with panel experts from India, Vietnam, Myanmar, Bangladesh, and Nepal. 1 April 2026 | 7:00 PM IST Registration link - rx-events.live/EXPERT-ROUNDTA… Looking forward to a thoughtful discussion on what matters in the real world: who benefits, when to intensify, and how LMIC realities shape decisions. @MirghSumeet @RahulDoc2 @nikhil91sjmc @DrPMPGI @Charanpreet_14 #MultipleMyeloma #Myeloma #Hematology #HemOnc #LMIC #mmsm #MedTwitter

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use. 3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk. 4) Use new IMWG IMS risk stratification 5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction). 6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.

What a #EHA2025, with multiple high-quality simultaneous publications! Congrats @EHA_Hematology and all presenters! Here are the most impressive malignant hematology studies🧵

Time to turn to #ClassicalHematology at #EHA2025 kicking off with my favorite topic: ITP. Boosting Platelets, discussing the challenges in ITP management by Dr. Carpenedo, Dr. Ghanima, and Dr. Lozano #Hematology #MedTwitter #Platelets #ITP